UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ: ORKA ) with a Buy and raises the price target from $100 to $130.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.